nodes	percent_of_prediction	percent_of_DWPC	metapath
Alitretinoin—CYP1A2—Progesterone—uterine cancer	0.0624	0.272	CbGbCtD
Alitretinoin—ABCB1—Progesterone—uterine cancer	0.0546	0.238	CbGbCtD
Alitretinoin—ABCB1—Dactinomycin—uterine cancer	0.0433	0.189	CbGbCtD
Alitretinoin—CYP1A2—Etoposide—uterine cancer	0.0279	0.122	CbGbCtD
Alitretinoin—ABCB1—Etoposide—uterine cancer	0.0244	0.107	CbGbCtD
Alitretinoin—ABCB1—Doxorubicin—uterine cancer	0.0167	0.0726	CbGbCtD
Alitretinoin—CRABP2—myometrium—uterine cancer	0.00677	0.0454	CbGeAlD
Alitretinoin—CRABP1—uterine cervix—uterine cancer	0.00583	0.039	CbGeAlD
Alitretinoin—CRABP2—uterine cervix—uterine cancer	0.00527	0.0353	CbGeAlD
Alitretinoin—CRABP2—smooth muscle tissue—uterine cancer	0.00512	0.0343	CbGeAlD
Alitretinoin—CRABP1—mammalian vulva—uterine cancer	0.0051	0.0342	CbGeAlD
Alitretinoin—CRABP2—decidua—uterine cancer	0.00502	0.0336	CbGeAlD
Alitretinoin—RXRA—renal system—uterine cancer	0.00491	0.0329	CbGeAlD
Alitretinoin—CRABP2—endometrium—uterine cancer	0.00477	0.0319	CbGeAlD
Alitretinoin—RARA—myometrium—uterine cancer	0.00465	0.0311	CbGeAlD
Alitretinoin—CRABP2—mammalian vulva—uterine cancer	0.00461	0.0309	CbGeAlD
Alitretinoin—CRABP1—female reproductive system—uterine cancer	0.00437	0.0293	CbGeAlD
Alitretinoin—RXRB—decidua—uterine cancer	0.00413	0.0276	CbGeAlD
Alitretinoin—CRABP1—vagina—uterine cancer	0.00395	0.0265	CbGeAlD
Alitretinoin—CRABP2—female reproductive system—uterine cancer	0.00395	0.0265	CbGeAlD
Alitretinoin—RXRA—female reproductive system—uterine cancer	0.00393	0.0263	CbGeAlD
Alitretinoin—RARG—decidua—uterine cancer	0.00366	0.0245	CbGeAlD
Alitretinoin—CRABP2—female gonad—uterine cancer	0.00359	0.0241	CbGeAlD
Alitretinoin—RXRA—female gonad—uterine cancer	0.00358	0.024	CbGeAlD
Alitretinoin—CRABP2—vagina—uterine cancer	0.00357	0.0239	CbGeAlD
Alitretinoin—RARB—female reproductive system—uterine cancer	0.00353	0.0237	CbGeAlD
Alitretinoin—RARA—decidua—uterine cancer	0.00344	0.0231	CbGeAlD
Alitretinoin—RARA—renal system—uterine cancer	0.00338	0.0227	CbGeAlD
Alitretinoin—RARG—mammalian vulva—uterine cancer	0.00336	0.0225	CbGeAlD
Alitretinoin—RARA—endometrium—uterine cancer	0.00327	0.0219	CbGeAlD
Alitretinoin—RARB—female gonad—uterine cancer	0.00321	0.0215	CbGeAlD
Alitretinoin—RARG—uterus—uterine cancer	0.0032	0.0215	CbGeAlD
Alitretinoin—RARB—vagina—uterine cancer	0.00319	0.0214	CbGeAlD
Alitretinoin—RARA—uterus—uterine cancer	0.00301	0.0202	CbGeAlD
Alitretinoin—RXRB—female gonad—uterine cancer	0.00295	0.0198	CbGeAlD
Alitretinoin—RXRB—vagina—uterine cancer	0.00293	0.0197	CbGeAlD
Alitretinoin—RARG—female reproductive system—uterine cancer	0.00288	0.0193	CbGeAlD
Alitretinoin—RARA—female reproductive system—uterine cancer	0.00271	0.0181	CbGeAlD
Alitretinoin—RARG—female gonad—uterine cancer	0.00262	0.0176	CbGeAlD
Alitretinoin—RARG—vagina—uterine cancer	0.00261	0.0175	CbGeAlD
Alitretinoin—RARA—female gonad—uterine cancer	0.00246	0.0165	CbGeAlD
Alitretinoin—RARB—lymph node—uterine cancer	0.00207	0.0138	CbGeAlD
Alitretinoin—RARG—lymph node—uterine cancer	0.00169	0.0113	CbGeAlD
Alitretinoin—RARA—lymph node—uterine cancer	0.00158	0.0106	CbGeAlD
Alitretinoin—CYP1A2—renal system—uterine cancer	0.00125	0.0084	CbGeAlD
Alitretinoin—ABCB1—myometrium—uterine cancer	0.000882	0.00591	CbGeAlD
Alitretinoin—ABCB1—epithelium—uterine cancer	0.000693	0.00464	CbGeAlD
Alitretinoin—ABCB1—uterine cervix—uterine cancer	0.000687	0.0046	CbGeAlD
Alitretinoin—ABCB1—decidua—uterine cancer	0.000654	0.00438	CbGeAlD
Alitretinoin—ABCB1—renal system—uterine cancer	0.000642	0.0043	CbGeAlD
Alitretinoin—ABCB1—endometrium—uterine cancer	0.000621	0.00416	CbGeAlD
Alitretinoin—ABCB1—mammalian vulva—uterine cancer	0.000601	0.00403	CbGeAlD
Alitretinoin—ABCB1—uterus—uterine cancer	0.000572	0.00383	CbGeAlD
Alitretinoin—ABCB1—female reproductive system—uterine cancer	0.000514	0.00345	CbGeAlD
Alitretinoin—ABCB1—female gonad—uterine cancer	0.000468	0.00314	CbGeAlD
Alitretinoin—ABCB1—vagina—uterine cancer	0.000465	0.00312	CbGeAlD
Alitretinoin—ABCB1—lymph node—uterine cancer	0.000301	0.00202	CbGeAlD
Alitretinoin—RXRA—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.000245	0.00124	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	0.000243	0.00123	CbGpPWpGaD
Alitretinoin—RARB—Generic Transcription Pathway—CDKN2B—uterine cancer	0.000242	0.00122	CbGpPWpGaD
Alitretinoin—CYP1A2—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000241	0.00122	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—DCN—uterine cancer	0.00024	0.00122	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—DCN—uterine cancer	0.00024	0.00122	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	0.000236	0.0012	CbGpPWpGaD
Alitretinoin—RXRA—a6b1 and a6b4 Integrin signaling—HRAS—uterine cancer	0.000235	0.00119	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—HNF1B—uterine cancer	0.000235	0.00119	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	0.000233	0.00118	CbGpPWpGaD
Alitretinoin—RXRB—Generic Transcription Pathway—CDKN2B—uterine cancer	0.000232	0.00117	CbGpPWpGaD
Alitretinoin—RARA—Generic Transcription Pathway—CDKN2B—uterine cancer	0.000232	0.00117	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—PHF1—uterine cancer	0.000229	0.00116	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	0.000227	0.00115	CbGpPWpGaD
Alitretinoin—CYP1A2—Metapathway biotransformation—AKR1B10—uterine cancer	0.000227	0.00115	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—CYP11A1—uterine cancer	0.000227	0.00115	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—CYP11A1—uterine cancer	0.000227	0.00115	CbGpPWpGaD
Alitretinoin—RXRG—Generic Transcription Pathway—SMAD3—uterine cancer	0.000225	0.00114	CbGpPWpGaD
Alitretinoin—RXRA—Transcriptional regulation of white adipocyte differentiation—EP300—uterine cancer	0.000224	0.00113	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	0.000223	0.00113	CbGpPWpGaD
Alitretinoin—RARB—Generic Transcription Pathway—SMAD3—uterine cancer	0.000221	0.00112	CbGpPWpGaD
Alitretinoin—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000219	0.00111	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	0.000218	0.0011	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	0.000216	0.00109	CbGpPWpGaD
Alitretinoin—CYP1A2—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.000216	0.00109	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—AKR1C3—uterine cancer	0.000214	0.00108	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—AKR1C3—uterine cancer	0.000214	0.00108	CbGpPWpGaD
Alitretinoin—RXRB—Generic Transcription Pathway—SMAD3—uterine cancer	0.000212	0.00107	CbGpPWpGaD
Alitretinoin—RARA—Generic Transcription Pathway—SMAD3—uterine cancer	0.000212	0.00107	CbGpPWpGaD
Alitretinoin—CYP1A2—Metapathway biotransformation—AKR1B1—uterine cancer	0.000211	0.00107	CbGpPWpGaD
Alitretinoin—RXRA—a6b1 and a6b4 Integrin signaling—AKT1—uterine cancer	0.000208	0.00105	CbGpPWpGaD
Alitretinoin—ABCB1—HIF-1-alpha transcription factor network—SMAD3—uterine cancer	0.000208	0.00105	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	0.000208	0.00105	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	0.000205	0.00104	CbGpPWpGaD
Alitretinoin—RARG—Generic Transcription Pathway—ESR1—uterine cancer	0.000201	0.00102	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	0.000201	0.00102	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	0.000197	0.000994	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—CHD4—uterine cancer	0.000194	0.000984	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	0.000189	0.000955	CbGpPWpGaD
Alitretinoin—Blood creatinine increased—Doxorubicin—uterine cancer	0.000186	0.000439	CcSEcCtD
Alitretinoin—Asthma—Epirubicin—uterine cancer	0.000185	0.000438	CcSEcCtD
Alitretinoin—Dysphagia—Epirubicin—uterine cancer	0.000185	0.000438	CcSEcCtD
Alitretinoin—Dehydration—Doxorubicin—uterine cancer	0.000185	0.000436	CcSEcCtD
Alitretinoin—Thrombocytopenia—Etoposide—uterine cancer	0.000184	0.000435	CcSEcCtD
Alitretinoin—RXRG—Generic Transcription Pathway—ESR1—uterine cancer	0.000184	0.000929	CbGpPWpGaD
Alitretinoin—Tachycardia—Etoposide—uterine cancer	0.000183	0.000433	CcSEcCtD
Alitretinoin—Skin disorder—Etoposide—uterine cancer	0.000183	0.000431	CcSEcCtD
Alitretinoin—Dry skin—Doxorubicin—uterine cancer	0.000182	0.000429	CcSEcCtD
Alitretinoin—Hyperhidrosis—Etoposide—uterine cancer	0.000182	0.000429	CcSEcCtD
Alitretinoin—Pancreatitis—Epirubicin—uterine cancer	0.000182	0.000429	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	0.000181	0.000917	CbGpPWpGaD
Alitretinoin—RARG—Gene Expression—PGR—uterine cancer	0.000181	0.000916	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—uterine cancer	0.000181	0.000913	CbGpPWpGaD
Alitretinoin—RARB—Generic Transcription Pathway—ESR1—uterine cancer	0.00018	0.000911	CbGpPWpGaD
Alitretinoin—Anorexia—Etoposide—uterine cancer	0.000179	0.000423	CcSEcCtD
Alitretinoin—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	0.000179	0.000422	CcSEcCtD
Alitretinoin—Diarrhoea—Dactinomycin—uterine cancer	0.000178	0.00042	CcSEcCtD
Alitretinoin—Nasopharyngitis—Doxorubicin—uterine cancer	0.000177	0.000419	CcSEcCtD
Alitretinoin—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000177	0.000896	CbGpPWpGaD
Alitretinoin—Hypotension—Etoposide—uterine cancer	0.000176	0.000415	CcSEcCtD
Alitretinoin—Gastritis—Doxorubicin—uterine cancer	0.000176	0.000415	CcSEcCtD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	0.000174	0.000882	CbGpPWpGaD
Alitretinoin—Neutropenia—Epirubicin—uterine cancer	0.000173	0.000409	CcSEcCtD
Alitretinoin—Dysuria—Epirubicin—uterine cancer	0.000173	0.000409	CcSEcCtD
Alitretinoin—RARA—Generic Transcription Pathway—ESR1—uterine cancer	0.000173	0.000874	CbGpPWpGaD
Alitretinoin—RXRB—Generic Transcription Pathway—ESR1—uterine cancer	0.000173	0.000874	CbGpPWpGaD
Alitretinoin—Abdominal distension—Doxorubicin—uterine cancer	0.000173	0.000408	CcSEcCtD
Alitretinoin—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000172	0.000407	CcSEcCtD
Alitretinoin—RARG—Gene Expression—EZH2—uterine cancer	0.000172	0.00087	CbGpPWpGaD
Alitretinoin—Dysphagia—Doxorubicin—uterine cancer	0.000171	0.000405	CcSEcCtD
Alitretinoin—Asthma—Doxorubicin—uterine cancer	0.000171	0.000405	CcSEcCtD
Alitretinoin—Pollakiuria—Epirubicin—uterine cancer	0.000171	0.000404	CcSEcCtD
Alitretinoin—Photosensitivity reaction—Epirubicin—uterine cancer	0.000169	0.000399	CcSEcCtD
Alitretinoin—Paraesthesia—Etoposide—uterine cancer	0.000169	0.000399	CcSEcCtD
Alitretinoin—Weight increased—Epirubicin—uterine cancer	0.000169	0.000398	CcSEcCtD
Alitretinoin—RXRA—Generic Transcription Pathway—PGR—uterine cancer	0.000169	0.000853	CbGpPWpGaD
Alitretinoin—RXRA—PPARA activates gene expression—EP300—uterine cancer	0.000168	0.000851	CbGpPWpGaD
Alitretinoin—Pancreatitis—Doxorubicin—uterine cancer	0.000168	0.000397	CcSEcCtD
Alitretinoin—Weight decreased—Epirubicin—uterine cancer	0.000168	0.000396	CcSEcCtD
Alitretinoin—Dyspnoea—Etoposide—uterine cancer	0.000168	0.000396	CcSEcCtD
Alitretinoin—Somnolence—Etoposide—uterine cancer	0.000167	0.000395	CcSEcCtD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	0.000167	0.000845	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—STK11—uterine cancer	0.000167	0.000843	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—STK11—uterine cancer	0.000167	0.000843	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—CYP19A1—uterine cancer	0.000167	0.000843	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—CYP19A1—uterine cancer	0.000167	0.000843	CbGpPWpGaD
Alitretinoin—Pneumonia—Epirubicin—uterine cancer	0.000166	0.000392	CcSEcCtD
Alitretinoin—RXRG—Gene Expression—PGR—uterine cancer	0.000166	0.000838	CbGpPWpGaD
Alitretinoin—Drowsiness—Epirubicin—uterine cancer	0.000165	0.00039	CcSEcCtD
Alitretinoin—Infestation NOS—Epirubicin—uterine cancer	0.000165	0.00039	CcSEcCtD
Alitretinoin—Infestation—Epirubicin—uterine cancer	0.000165	0.00039	CcSEcCtD
Alitretinoin—Vomiting—Dactinomycin—uterine cancer	0.000165	0.00039	CcSEcCtD
Alitretinoin—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—uterine cancer	0.000165	0.000833	CbGpPWpGaD
Alitretinoin—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000164	0.000387	CcSEcCtD
Alitretinoin—Rash—Dactinomycin—uterine cancer	0.000164	0.000387	CcSEcCtD
Alitretinoin—Decreased appetite—Etoposide—uterine cancer	0.000163	0.000386	CcSEcCtD
Alitretinoin—RXRA—Gene Expression—SUZ12—uterine cancer	0.000163	0.000824	CbGpPWpGaD
Alitretinoin—Renal failure—Epirubicin—uterine cancer	0.000162	0.000383	CcSEcCtD
Alitretinoin—RARB—Gene Expression—PGR—uterine cancer	0.000162	0.000822	CbGpPWpGaD
Alitretinoin—Gastrointestinal disorder—Etoposide—uterine cancer	0.000162	0.000383	CcSEcCtD
Alitretinoin—Fatigue—Etoposide—uterine cancer	0.000162	0.000383	CcSEcCtD
Alitretinoin—Neuropathy peripheral—Epirubicin—uterine cancer	0.000162	0.000382	CcSEcCtD
Alitretinoin—Stomatitis—Epirubicin—uterine cancer	0.000161	0.00038	CcSEcCtD
Alitretinoin—Pain—Etoposide—uterine cancer	0.000161	0.00038	CcSEcCtD
Alitretinoin—Constipation—Etoposide—uterine cancer	0.000161	0.00038	CcSEcCtD
Alitretinoin—Urinary tract infection—Epirubicin—uterine cancer	0.000161	0.000379	CcSEcCtD
Alitretinoin—Conjunctivitis—Epirubicin—uterine cancer	0.000161	0.000379	CcSEcCtD
Alitretinoin—Neutropenia—Doxorubicin—uterine cancer	0.00016	0.000379	CcSEcCtD
Alitretinoin—Dysuria—Doxorubicin—uterine cancer	0.00016	0.000379	CcSEcCtD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	0.00016	0.00081	CbGpPWpGaD
Alitretinoin—RARG—Gene Expression—ESR2—uterine cancer	0.000159	0.000806	CbGpPWpGaD
Alitretinoin—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000159	0.000376	CcSEcCtD
Alitretinoin—RXRA—Metabolism—NDUFB11—uterine cancer	0.000159	0.000802	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—SRD5A2—uterine cancer	0.000159	0.000802	CbGpPWpGaD
Alitretinoin—Sweating—Epirubicin—uterine cancer	0.000158	0.000374	CcSEcCtD
Alitretinoin—Pollakiuria—Doxorubicin—uterine cancer	0.000158	0.000374	CcSEcCtD
Alitretinoin—RXRA—Adipogenesis—CTNNB1—uterine cancer	0.000158	0.000801	CbGpPWpGaD
Alitretinoin—Haematuria—Epirubicin—uterine cancer	0.000158	0.000372	CcSEcCtD
Alitretinoin—RXRG—Gene Expression—EZH2—uterine cancer	0.000157	0.000796	CbGpPWpGaD
Alitretinoin—Photosensitivity reaction—Doxorubicin—uterine cancer	0.000157	0.00037	CcSEcCtD
Alitretinoin—CRABP1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	0.000156	0.000791	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	0.000156	0.000791	CbGpPWpGaD
Alitretinoin—Weight increased—Doxorubicin—uterine cancer	0.000156	0.000368	CcSEcCtD
Alitretinoin—Epistaxis—Epirubicin—uterine cancer	0.000156	0.000368	CcSEcCtD
Alitretinoin—RARA—Gene Expression—PGR—uterine cancer	0.000156	0.000788	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—PGR—uterine cancer	0.000156	0.000788	CbGpPWpGaD
Alitretinoin—Weight decreased—Doxorubicin—uterine cancer	0.000155	0.000366	CcSEcCtD
Alitretinoin—Sinusitis—Epirubicin—uterine cancer	0.000155	0.000366	CcSEcCtD
Alitretinoin—Feeling abnormal—Etoposide—uterine cancer	0.000155	0.000366	CcSEcCtD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	0.000155	0.000784	CbGpPWpGaD
Alitretinoin—CYP1A2—Metapathway biotransformation—AKR1C1—uterine cancer	0.000155	0.000783	CbGpPWpGaD
Alitretinoin—Nausea—Dactinomycin—uterine cancer	0.000154	0.000364	CcSEcCtD
Alitretinoin—RARB—Gene Expression—EZH2—uterine cancer	0.000154	0.00078	CbGpPWpGaD
Alitretinoin—Agranulocytosis—Epirubicin—uterine cancer	0.000154	0.000364	CcSEcCtD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	0.000154	0.000779	CbGpPWpGaD
Alitretinoin—Pneumonia—Doxorubicin—uterine cancer	0.000154	0.000363	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Etoposide—uterine cancer	0.000154	0.000363	CcSEcCtD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	0.000154	0.000777	CbGpPWpGaD
Alitretinoin—Infestation—Doxorubicin—uterine cancer	0.000153	0.000361	CcSEcCtD
Alitretinoin—Drowsiness—Doxorubicin—uterine cancer	0.000153	0.000361	CcSEcCtD
Alitretinoin—Infestation NOS—Doxorubicin—uterine cancer	0.000153	0.000361	CcSEcCtD
Alitretinoin—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.000152	0.000358	CcSEcCtD
Alitretinoin—Renal failure—Doxorubicin—uterine cancer	0.00015	0.000355	CcSEcCtD
Alitretinoin—Neuropathy peripheral—Doxorubicin—uterine cancer	0.00015	0.000354	CcSEcCtD
Alitretinoin—Urticaria—Etoposide—uterine cancer	0.000149	0.000353	CcSEcCtD
Alitretinoin—CRABP1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	0.000149	0.000755	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	0.000149	0.000755	CbGpPWpGaD
Alitretinoin—Haemoglobin—Epirubicin—uterine cancer	0.000149	0.000352	CcSEcCtD
Alitretinoin—Stomatitis—Doxorubicin—uterine cancer	0.000149	0.000352	CcSEcCtD
Alitretinoin—Body temperature increased—Etoposide—uterine cancer	0.000149	0.000351	CcSEcCtD
Alitretinoin—Abdominal pain—Etoposide—uterine cancer	0.000149	0.000351	CcSEcCtD
Alitretinoin—Conjunctivitis—Doxorubicin—uterine cancer	0.000149	0.000351	CcSEcCtD
Alitretinoin—Urinary tract infection—Doxorubicin—uterine cancer	0.000149	0.000351	CcSEcCtD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	0.000149	0.000751	CbGpPWpGaD
Alitretinoin—RXRA—Generic Transcription Pathway—ESR2—uterine cancer	0.000148	0.000751	CbGpPWpGaD
Alitretinoin—Haemorrhage—Epirubicin—uterine cancer	0.000148	0.00035	CcSEcCtD
Alitretinoin—Hepatitis—Epirubicin—uterine cancer	0.000148	0.00035	CcSEcCtD
Alitretinoin—RARA—Gene Expression—EZH2—uterine cancer	0.000148	0.000748	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—EZH2—uterine cancer	0.000148	0.000748	CbGpPWpGaD
Alitretinoin—Hypoaesthesia—Epirubicin—uterine cancer	0.000148	0.000348	CcSEcCtD
Alitretinoin—Pharyngitis—Epirubicin—uterine cancer	0.000147	0.000348	CcSEcCtD
Alitretinoin—Sweating—Doxorubicin—uterine cancer	0.000147	0.000346	CcSEcCtD
Alitretinoin—Urinary tract disorder—Epirubicin—uterine cancer	0.000146	0.000346	CcSEcCtD
Alitretinoin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—uterine cancer	0.000146	0.000739	CbGpPWpGaD
Alitretinoin—Oedema peripheral—Epirubicin—uterine cancer	0.000146	0.000345	CcSEcCtD
Alitretinoin—RXRG—Gene Expression—ESR2—uterine cancer	0.000146	0.000738	CbGpPWpGaD
Alitretinoin—Haematuria—Doxorubicin—uterine cancer	0.000146	0.000344	CcSEcCtD
Alitretinoin—Urethral disorder—Epirubicin—uterine cancer	0.000145	0.000343	CcSEcCtD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	0.000145	0.000736	CbGpPWpGaD
Alitretinoin—Epistaxis—Doxorubicin—uterine cancer	0.000144	0.00034	CcSEcCtD
Alitretinoin—Sinusitis—Doxorubicin—uterine cancer	0.000143	0.000339	CcSEcCtD
Alitretinoin—RARB—Gene Expression—ESR2—uterine cancer	0.000143	0.000723	CbGpPWpGaD
Alitretinoin—Visual impairment—Epirubicin—uterine cancer	0.000143	0.000337	CcSEcCtD
Alitretinoin—Agranulocytosis—Doxorubicin—uterine cancer	0.000143	0.000337	CcSEcCtD
Alitretinoin—Erythema multiforme—Epirubicin—uterine cancer	0.00014	0.000331	CcSEcCtD
Alitretinoin—Eye disorder—Epirubicin—uterine cancer	0.000139	0.000327	CcSEcCtD
Alitretinoin—Hypersensitivity—Etoposide—uterine cancer	0.000139	0.000327	CcSEcCtD
Alitretinoin—Tinnitus—Epirubicin—uterine cancer	0.000138	0.000327	CcSEcCtD
Alitretinoin—Haemoglobin—Doxorubicin—uterine cancer	0.000138	0.000326	CcSEcCtD
Alitretinoin—Flushing—Epirubicin—uterine cancer	0.000138	0.000325	CcSEcCtD
Alitretinoin—Haemorrhage—Doxorubicin—uterine cancer	0.000137	0.000324	CcSEcCtD
Alitretinoin—Hepatitis—Doxorubicin—uterine cancer	0.000137	0.000324	CcSEcCtD
Alitretinoin—RARA—Gene Expression—ESR2—uterine cancer	0.000137	0.000694	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—ESR2—uterine cancer	0.000137	0.000694	CbGpPWpGaD
Alitretinoin—Hypoaesthesia—Doxorubicin—uterine cancer	0.000137	0.000322	CcSEcCtD
Alitretinoin—Pharyngitis—Doxorubicin—uterine cancer	0.000136	0.000322	CcSEcCtD
Alitretinoin—CYP1A2—Metapathway biotransformation—GPX3—uterine cancer	0.000136	0.000687	CbGpPWpGaD
Alitretinoin—Urinary tract disorder—Doxorubicin—uterine cancer	0.000136	0.00032	CcSEcCtD
Alitretinoin—Oedema peripheral—Doxorubicin—uterine cancer	0.000135	0.000319	CcSEcCtD
Alitretinoin—Asthenia—Etoposide—uterine cancer	0.000135	0.000318	CcSEcCtD
Alitretinoin—Angiopathy—Epirubicin—uterine cancer	0.000135	0.000318	CcSEcCtD
Alitretinoin—Urethral disorder—Doxorubicin—uterine cancer	0.000135	0.000318	CcSEcCtD
Alitretinoin—Chills—Epirubicin—uterine cancer	0.000133	0.000314	CcSEcCtD
Alitretinoin—Pruritus—Etoposide—uterine cancer	0.000133	0.000314	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	0.000133	0.000673	CbGpPWpGaD
Alitretinoin—Arrhythmia—Epirubicin—uterine cancer	0.000133	0.000313	CcSEcCtD
Alitretinoin—Visual impairment—Doxorubicin—uterine cancer	0.000132	0.000312	CcSEcCtD
Alitretinoin—Alopecia—Epirubicin—uterine cancer	0.000131	0.000309	CcSEcCtD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	0.000131	0.000662	CbGpPWpGaD
Alitretinoin—Mental disorder—Epirubicin—uterine cancer	0.00013	0.000307	CcSEcCtD
Alitretinoin—RARG—Gene Expression—CDKN2B—uterine cancer	0.00013	0.000656	CbGpPWpGaD
Alitretinoin—Erythema multiforme—Doxorubicin—uterine cancer	0.00013	0.000306	CcSEcCtD
Alitretinoin—Malnutrition—Epirubicin—uterine cancer	0.000129	0.000305	CcSEcCtD
Alitretinoin—Erythema—Epirubicin—uterine cancer	0.000129	0.000305	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	0.000129	0.000652	CbGpPWpGaD
Alitretinoin—Diarrhoea—Etoposide—uterine cancer	0.000129	0.000304	CcSEcCtD
Alitretinoin—Eye disorder—Doxorubicin—uterine cancer	0.000128	0.000303	CcSEcCtD
Alitretinoin—Tinnitus—Doxorubicin—uterine cancer	0.000128	0.000302	CcSEcCtD
Alitretinoin—CYP1A2—Biological oxidations—CYP11A1—uterine cancer	0.000128	0.000647	CbGpPWpGaD
Alitretinoin—Flushing—Doxorubicin—uterine cancer	0.000127	0.000301	CcSEcCtD
Alitretinoin—Flatulence—Epirubicin—uterine cancer	0.000127	0.0003	CcSEcCtD
Alitretinoin—Tension—Epirubicin—uterine cancer	0.000127	0.000299	CcSEcCtD
Alitretinoin—CYP1A2—Metapathway biotransformation—CYP11A1—uterine cancer	0.000126	0.000638	CbGpPWpGaD
Alitretinoin—Nervousness—Epirubicin—uterine cancer	0.000125	0.000296	CcSEcCtD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	0.000125	0.000634	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—MTHFR—uterine cancer	0.000125	0.000633	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—MTHFR—uterine cancer	0.000125	0.000633	CbGpPWpGaD
Alitretinoin—Back pain—Epirubicin—uterine cancer	0.000125	0.000295	CcSEcCtD
Alitretinoin—Angiopathy—Doxorubicin—uterine cancer	0.000125	0.000294	CcSEcCtD
Alitretinoin—Dizziness—Etoposide—uterine cancer	0.000124	0.000294	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	0.000123	0.000623	CbGpPWpGaD
Alitretinoin—Chills—Doxorubicin—uterine cancer	0.000123	0.000291	CcSEcCtD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—uterine cancer	0.000123	0.000621	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—uterine cancer	0.000123	0.000621	CbGpPWpGaD
Alitretinoin—Arrhythmia—Doxorubicin—uterine cancer	0.000123	0.000289	CcSEcCtD
Alitretinoin—Vision blurred—Epirubicin—uterine cancer	0.000122	0.000287	CcSEcCtD
Alitretinoin—Alopecia—Doxorubicin—uterine cancer	0.000121	0.000286	CcSEcCtD
Alitretinoin—RXRA—Generic Transcription Pathway—CDKN2B—uterine cancer	0.000121	0.000611	CbGpPWpGaD
Alitretinoin—Mental disorder—Doxorubicin—uterine cancer	0.00012	0.000284	CcSEcCtD
Alitretinoin—Ill-defined disorder—Epirubicin—uterine cancer	0.00012	0.000283	CcSEcCtD
Alitretinoin—Vomiting—Etoposide—uterine cancer	0.00012	0.000282	CcSEcCtD
Alitretinoin—Erythema—Doxorubicin—uterine cancer	0.000119	0.000282	CcSEcCtD
Alitretinoin—Malnutrition—Doxorubicin—uterine cancer	0.000119	0.000282	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	0.000119	0.000604	CbGpPWpGaD
Alitretinoin—Anaemia—Epirubicin—uterine cancer	0.000119	0.000282	CcSEcCtD
Alitretinoin—CYP1A2—Metapathway biotransformation—AKR1C3—uterine cancer	0.000119	0.000603	CbGpPWpGaD
Alitretinoin—RXRG—Gene Expression—CDKN2B—uterine cancer	0.000119	0.0006	CbGpPWpGaD
Alitretinoin—Agitation—Epirubicin—uterine cancer	0.000119	0.00028	CcSEcCtD
Alitretinoin—Rash—Etoposide—uterine cancer	0.000119	0.00028	CcSEcCtD
Alitretinoin—RARG—Gene Expression—SMAD3—uterine cancer	0.000118	0.000599	CbGpPWpGaD
Alitretinoin—Dermatitis—Etoposide—uterine cancer	0.000118	0.00028	CcSEcCtD
Alitretinoin—Headache—Etoposide—uterine cancer	0.000118	0.000278	CcSEcCtD
Alitretinoin—Flatulence—Doxorubicin—uterine cancer	0.000118	0.000278	CcSEcCtD
Alitretinoin—Tension—Doxorubicin—uterine cancer	0.000117	0.000277	CcSEcCtD
Alitretinoin—Malaise—Epirubicin—uterine cancer	0.000116	0.000275	CcSEcCtD
Alitretinoin—RARB—Gene Expression—CDKN2B—uterine cancer	0.000116	0.000589	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	0.000116	0.000589	CbGpPWpGaD
Alitretinoin—Nervousness—Doxorubicin—uterine cancer	0.000116	0.000274	CcSEcCtD
Alitretinoin—Syncope—Epirubicin—uterine cancer	0.000116	0.000273	CcSEcCtD
Alitretinoin—Back pain—Doxorubicin—uterine cancer	0.000116	0.000273	CcSEcCtD
Alitretinoin—RXRA—Metabolism—STAR—uterine cancer	0.000115	0.00058	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—AKR1B1—uterine cancer	0.000115	0.00058	CbGpPWpGaD
Alitretinoin—Palpitations—Epirubicin—uterine cancer	0.000114	0.000269	CcSEcCtD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.000114	0.000574	CbGpPWpGaD
Alitretinoin—Loss of consciousness—Epirubicin—uterine cancer	0.000113	0.000268	CcSEcCtD
Alitretinoin—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—uterine cancer	0.000113	0.000574	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	0.000113	0.000574	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	0.000113	0.000573	CbGpPWpGaD
Alitretinoin—Cough—Epirubicin—uterine cancer	0.000113	0.000266	CcSEcCtD
Alitretinoin—Vision blurred—Doxorubicin—uterine cancer	0.000113	0.000266	CcSEcCtD
Alitretinoin—Convulsion—Epirubicin—uterine cancer	0.000112	0.000264	CcSEcCtD
Alitretinoin—Nausea—Etoposide—uterine cancer	0.000112	0.000264	CcSEcCtD
Alitretinoin—RARA—Gene Expression—CDKN2B—uterine cancer	0.000112	0.000565	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—CDKN2B—uterine cancer	0.000112	0.000565	CbGpPWpGaD
Alitretinoin—Hypertension—Epirubicin—uterine cancer	0.000111	0.000263	CcSEcCtD
Alitretinoin—Ill-defined disorder—Doxorubicin—uterine cancer	0.000111	0.000262	CcSEcCtD
Alitretinoin—Anaemia—Doxorubicin—uterine cancer	0.00011	0.000261	CcSEcCtD
Alitretinoin—CRABP2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	0.00011	0.000558	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	0.00011	0.000558	CbGpPWpGaD
Alitretinoin—RXRA—Generic Transcription Pathway—SMAD3—uterine cancer	0.00011	0.000558	CbGpPWpGaD
Alitretinoin—Arthralgia—Epirubicin—uterine cancer	0.00011	0.00026	CcSEcCtD
Alitretinoin—Chest pain—Epirubicin—uterine cancer	0.00011	0.00026	CcSEcCtD
Alitretinoin—Myalgia—Epirubicin—uterine cancer	0.00011	0.00026	CcSEcCtD
Alitretinoin—Agitation—Doxorubicin—uterine cancer	0.00011	0.000259	CcSEcCtD
Alitretinoin—Anxiety—Epirubicin—uterine cancer	0.00011	0.000259	CcSEcCtD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000109	0.000258	CcSEcCtD
Alitretinoin—Discomfort—Epirubicin—uterine cancer	0.000109	0.000256	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	0.000108	0.000548	CbGpPWpGaD
Alitretinoin—RXRG—Gene Expression—SMAD3—uterine cancer	0.000108	0.000548	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	0.000108	0.000547	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—EP300—uterine cancer	0.000108	0.000545	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—uterine cancer	0.000108	0.000545	CbGpPWpGaD
Alitretinoin—Malaise—Doxorubicin—uterine cancer	0.000108	0.000254	CcSEcCtD
Alitretinoin—Dry mouth—Epirubicin—uterine cancer	0.000108	0.000254	CcSEcCtD
Alitretinoin—Syncope—Doxorubicin—uterine cancer	0.000107	0.000253	CcSEcCtD
Alitretinoin—RARB—Gene Expression—SMAD3—uterine cancer	0.000106	0.000538	CbGpPWpGaD
Alitretinoin—Confusional state—Epirubicin—uterine cancer	0.000106	0.000251	CcSEcCtD
Alitretinoin—Palpitations—Doxorubicin—uterine cancer	0.000106	0.000249	CcSEcCtD
Alitretinoin—Oedema—Epirubicin—uterine cancer	0.000105	0.000249	CcSEcCtD
Alitretinoin—Anaphylactic shock—Epirubicin—uterine cancer	0.000105	0.000249	CcSEcCtD
Alitretinoin—Loss of consciousness—Doxorubicin—uterine cancer	0.000105	0.000248	CcSEcCtD
Alitretinoin—Infection—Epirubicin—uterine cancer	0.000105	0.000247	CcSEcCtD
Alitretinoin—Cough—Doxorubicin—uterine cancer	0.000104	0.000246	CcSEcCtD
Alitretinoin—RXRA—Developmental Biology—SMAD3—uterine cancer	0.000104	0.000525	CbGpPWpGaD
Alitretinoin—Shock—Epirubicin—uterine cancer	0.000104	0.000245	CcSEcCtD
Alitretinoin—Convulsion—Doxorubicin—uterine cancer	0.000104	0.000244	CcSEcCtD
Alitretinoin—Nervous system disorder—Epirubicin—uterine cancer	0.000103	0.000244	CcSEcCtD
Alitretinoin—Thrombocytopenia—Epirubicin—uterine cancer	0.000103	0.000244	CcSEcCtD
Alitretinoin—Hypertension—Doxorubicin—uterine cancer	0.000103	0.000244	CcSEcCtD
Alitretinoin—Tachycardia—Epirubicin—uterine cancer	0.000103	0.000243	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	0.000102	0.000518	CbGpPWpGaD
Alitretinoin—Skin disorder—Epirubicin—uterine cancer	0.000102	0.000242	CcSEcCtD
Alitretinoin—ABCB1—Allograft Rejection—CXCL8—uterine cancer	0.000102	0.000517	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—uterine cancer	0.000102	0.000516	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—SMAD3—uterine cancer	0.000102	0.000515	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—SMAD3—uterine cancer	0.000102	0.000515	CbGpPWpGaD
Alitretinoin—Hyperhidrosis—Epirubicin—uterine cancer	0.000102	0.000241	CcSEcCtD
Alitretinoin—Arthralgia—Doxorubicin—uterine cancer	0.000102	0.00024	CcSEcCtD
Alitretinoin—Myalgia—Doxorubicin—uterine cancer	0.000102	0.00024	CcSEcCtD
Alitretinoin—Chest pain—Doxorubicin—uterine cancer	0.000102	0.00024	CcSEcCtD
Alitretinoin—Anxiety—Doxorubicin—uterine cancer	0.000101	0.000239	CcSEcCtD
Alitretinoin—ABCB1—HIF-1-alpha transcription factor network—EP300—uterine cancer	0.000101	0.000512	CbGpPWpGaD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000101	0.000238	CcSEcCtD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—uterine cancer	0.000101	0.00051	CbGpPWpGaD
Alitretinoin—Discomfort—Doxorubicin—uterine cancer	0.000101	0.000237	CcSEcCtD
Alitretinoin—Anorexia—Epirubicin—uterine cancer	0.0001	0.000237	CcSEcCtD
Alitretinoin—Dry mouth—Doxorubicin—uterine cancer	9.95e-05	0.000235	CcSEcCtD
Alitretinoin—Hypotension—Epirubicin—uterine cancer	9.85e-05	0.000232	CcSEcCtD
Alitretinoin—Confusional state—Doxorubicin—uterine cancer	9.83e-05	0.000232	CcSEcCtD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—ABCC9—uterine cancer	9.78e-05	0.000495	CbGpPWpGaD
Alitretinoin—Anaphylactic shock—Doxorubicin—uterine cancer	9.75e-05	0.00023	CcSEcCtD
Alitretinoin—Oedema—Doxorubicin—uterine cancer	9.75e-05	0.00023	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	9.72e-05	0.000492	CbGpPWpGaD
Alitretinoin—Infection—Doxorubicin—uterine cancer	9.69e-05	0.000229	CcSEcCtD
Alitretinoin—RARG—Gene Expression—ESR1—uterine cancer	9.67e-05	0.000489	CbGpPWpGaD
Alitretinoin—Musculoskeletal discomfort—Epirubicin—uterine cancer	9.6e-05	0.000227	CcSEcCtD
Alitretinoin—Shock—Doxorubicin—uterine cancer	9.59e-05	0.000226	CcSEcCtD
Alitretinoin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—uterine cancer	9.58e-05	0.000485	CbGpPWpGaD
Alitretinoin—Nervous system disorder—Doxorubicin—uterine cancer	9.56e-05	0.000226	CcSEcCtD
Alitretinoin—Thrombocytopenia—Doxorubicin—uterine cancer	9.55e-05	0.000225	CcSEcCtD
Alitretinoin—Insomnia—Epirubicin—uterine cancer	9.53e-05	0.000225	CcSEcCtD
Alitretinoin—Tachycardia—Doxorubicin—uterine cancer	9.52e-05	0.000225	CcSEcCtD
Alitretinoin—Skin disorder—Doxorubicin—uterine cancer	9.47e-05	0.000224	CcSEcCtD
Alitretinoin—Paraesthesia—Epirubicin—uterine cancer	9.46e-05	0.000223	CcSEcCtD
Alitretinoin—Hyperhidrosis—Doxorubicin—uterine cancer	9.43e-05	0.000223	CcSEcCtD
Alitretinoin—CYP1A2—Biological oxidations—CYP19A1—uterine cancer	9.41e-05	0.000476	CbGpPWpGaD
Alitretinoin—Dyspnoea—Epirubicin—uterine cancer	9.4e-05	0.000222	CcSEcCtD
Alitretinoin—Somnolence—Epirubicin—uterine cancer	9.37e-05	0.000221	CcSEcCtD
Alitretinoin—Anorexia—Doxorubicin—uterine cancer	9.3e-05	0.000219	CcSEcCtD
Alitretinoin—CYP1A2—Metapathway biotransformation—CYP19A1—uterine cancer	9.28e-05	0.00047	CbGpPWpGaD
Alitretinoin—Dyspepsia—Epirubicin—uterine cancer	9.28e-05	0.000219	CcSEcCtD
Alitretinoin—Decreased appetite—Epirubicin—uterine cancer	9.16e-05	0.000216	CcSEcCtD
Alitretinoin—Hypotension—Doxorubicin—uterine cancer	9.11e-05	0.000215	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Epirubicin—uterine cancer	9.1e-05	0.000215	CcSEcCtD
Alitretinoin—Fatigue—Epirubicin—uterine cancer	9.09e-05	0.000214	CcSEcCtD
Alitretinoin—Constipation—Epirubicin—uterine cancer	9.01e-05	0.000213	CcSEcCtD
Alitretinoin—Pain—Epirubicin—uterine cancer	9.01e-05	0.000213	CcSEcCtD
Alitretinoin—RXRA—Generic Transcription Pathway—ESR1—uterine cancer	9e-05	0.000455	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—POLD1—uterine cancer	8.99e-05	0.000455	CbGpPWpGaD
Alitretinoin—Musculoskeletal discomfort—Doxorubicin—uterine cancer	8.88e-05	0.00021	CcSEcCtD
Alitretinoin—RXRG—Gene Expression—ESR1—uterine cancer	8.84e-05	0.000447	CbGpPWpGaD
Alitretinoin—Insomnia—Doxorubicin—uterine cancer	8.82e-05	0.000208	CcSEcCtD
Alitretinoin—Paraesthesia—Doxorubicin—uterine cancer	8.76e-05	0.000207	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	8.71e-05	0.000441	CbGpPWpGaD
Alitretinoin—Dyspnoea—Doxorubicin—uterine cancer	8.69e-05	0.000205	CcSEcCtD
Alitretinoin—Feeling abnormal—Epirubicin—uterine cancer	8.68e-05	0.000205	CcSEcCtD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	8.68e-05	0.000439	CbGpPWpGaD
Alitretinoin—RARB—Gene Expression—ESR1—uterine cancer	8.67e-05	0.000439	CbGpPWpGaD
Alitretinoin—Somnolence—Doxorubicin—uterine cancer	8.67e-05	0.000205	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Epirubicin—uterine cancer	8.62e-05	0.000203	CcSEcCtD
Alitretinoin—Dyspepsia—Doxorubicin—uterine cancer	8.58e-05	0.000203	CcSEcCtD
Alitretinoin—RXRA—Developmental Biology—MET—uterine cancer	8.51e-05	0.00043	CbGpPWpGaD
Alitretinoin—Decreased appetite—Doxorubicin—uterine cancer	8.48e-05	0.0002	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Doxorubicin—uterine cancer	8.42e-05	0.000199	CcSEcCtD
Alitretinoin—RXRA—Metabolism—AKR1C1—uterine cancer	8.41e-05	0.000426	CbGpPWpGaD
Alitretinoin—Fatigue—Doxorubicin—uterine cancer	8.41e-05	0.000198	CcSEcCtD
Alitretinoin—Urticaria—Epirubicin—uterine cancer	8.37e-05	0.000198	CcSEcCtD
Alitretinoin—Constipation—Doxorubicin—uterine cancer	8.34e-05	0.000197	CcSEcCtD
Alitretinoin—Pain—Doxorubicin—uterine cancer	8.34e-05	0.000197	CcSEcCtD
Alitretinoin—Body temperature increased—Epirubicin—uterine cancer	8.33e-05	0.000197	CcSEcCtD
Alitretinoin—Abdominal pain—Epirubicin—uterine cancer	8.33e-05	0.000197	CcSEcCtD
Alitretinoin—RXRB—Gene Expression—ESR1—uterine cancer	8.32e-05	0.000421	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—ESR1—uterine cancer	8.32e-05	0.000421	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—VEGFA—uterine cancer	8.3e-05	0.00042	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—STAR—uterine cancer	8.21e-05	0.000415	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	8.21e-05	0.000415	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—PGR—uterine cancer	8.12e-05	0.000411	CbGpPWpGaD
Alitretinoin—Feeling abnormal—Doxorubicin—uterine cancer	8.04e-05	0.00019	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	8e-05	0.000405	CbGpPWpGaD
Alitretinoin—Gastrointestinal pain—Doxorubicin—uterine cancer	7.97e-05	0.000188	CcSEcCtD
Alitretinoin—Hypersensitivity—Epirubicin—uterine cancer	7.76e-05	0.000183	CcSEcCtD
Alitretinoin—Urticaria—Doxorubicin—uterine cancer	7.75e-05	0.000183	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	7.74e-05	0.000392	CbGpPWpGaD
Alitretinoin—Abdominal pain—Doxorubicin—uterine cancer	7.71e-05	0.000182	CcSEcCtD
Alitretinoin—Body temperature increased—Doxorubicin—uterine cancer	7.71e-05	0.000182	CcSEcCtD
Alitretinoin—RXRA—Gene Expression—EZH2—uterine cancer	7.71e-05	0.00039	CbGpPWpGaD
Alitretinoin—Asthenia—Epirubicin—uterine cancer	7.56e-05	0.000179	CcSEcCtD
Alitretinoin—RXRA—Metabolism—RRM2—uterine cancer	7.5e-05	0.000379	CbGpPWpGaD
Alitretinoin—Pruritus—Epirubicin—uterine cancer	7.46e-05	0.000176	CcSEcCtD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	7.38e-05	0.000373	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—DCN—uterine cancer	7.28e-05	0.000368	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	7.24e-05	0.000366	CbGpPWpGaD
Alitretinoin—Diarrhoea—Epirubicin—uterine cancer	7.21e-05	0.00017	CcSEcCtD
Alitretinoin—Hypersensitivity—Doxorubicin—uterine cancer	7.18e-05	0.00017	CcSEcCtD
Alitretinoin—RXRA—Gene Expression—ESR2—uterine cancer	7.15e-05	0.000361	CbGpPWpGaD
Alitretinoin—Asthenia—Doxorubicin—uterine cancer	7e-05	0.000165	CcSEcCtD
Alitretinoin—Dizziness—Epirubicin—uterine cancer	6.97e-05	0.000165	CcSEcCtD
Alitretinoin—CRABP1—Metabolism—PTEN—uterine cancer	6.97e-05	0.000352	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—PTEN—uterine cancer	6.97e-05	0.000352	CbGpPWpGaD
Alitretinoin—Pruritus—Doxorubicin—uterine cancer	6.9e-05	0.000163	CcSEcCtD
Alitretinoin—RXRA—Metabolism—CYP11A1—uterine cancer	6.86e-05	0.000347	CbGpPWpGaD
Alitretinoin—Vomiting—Epirubicin—uterine cancer	6.7e-05	0.000158	CcSEcCtD
Alitretinoin—Diarrhoea—Doxorubicin—uterine cancer	6.67e-05	0.000158	CcSEcCtD
Alitretinoin—Rash—Epirubicin—uterine cancer	6.65e-05	0.000157	CcSEcCtD
Alitretinoin—CRABP1—Metabolism—EP300—uterine cancer	6.64e-05	0.000336	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—EP300—uterine cancer	6.64e-05	0.000336	CbGpPWpGaD
Alitretinoin—Dermatitis—Epirubicin—uterine cancer	6.64e-05	0.000157	CcSEcCtD
Alitretinoin—Headache—Epirubicin—uterine cancer	6.6e-05	0.000156	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	6.54e-05	0.000331	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—AKR1C3—uterine cancer	6.48e-05	0.000328	CbGpPWpGaD
Alitretinoin—Dizziness—Doxorubicin—uterine cancer	6.45e-05	0.000152	CcSEcCtD
Alitretinoin—ABCB1—Metabolism—NDUFB11—uterine cancer	6.34e-05	0.00032	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—SRD5A2—uterine cancer	6.34e-05	0.00032	CbGpPWpGaD
Alitretinoin—Nausea—Epirubicin—uterine cancer	6.26e-05	0.000148	CcSEcCtD
Alitretinoin—RXRA—Developmental Biology—ERBB2—uterine cancer	6.22e-05	0.000315	CbGpPWpGaD
Alitretinoin—Vomiting—Doxorubicin—uterine cancer	6.2e-05	0.000146	CcSEcCtD
Alitretinoin—Rash—Doxorubicin—uterine cancer	6.15e-05	0.000145	CcSEcCtD
Alitretinoin—Dermatitis—Doxorubicin—uterine cancer	6.14e-05	0.000145	CcSEcCtD
Alitretinoin—ABCB1—HIF-1-alpha transcription factor network—AKT1—uterine cancer	6.11e-05	0.000309	CbGpPWpGaD
Alitretinoin—Headache—Doxorubicin—uterine cancer	6.11e-05	0.000144	CcSEcCtD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	6.03e-05	0.000305	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—CDKN2B—uterine cancer	5.82e-05	0.000294	CbGpPWpGaD
Alitretinoin—Nausea—Doxorubicin—uterine cancer	5.79e-05	0.000137	CcSEcCtD
Alitretinoin—RXRA—Developmental Biology—CTNNB1—uterine cancer	5.44e-05	0.000275	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	5.31e-05	0.000269	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—SMAD3—uterine cancer	5.31e-05	0.000269	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—SRD5A2—uterine cancer	5.06e-05	0.000256	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—NDUFB11—uterine cancer	5.06e-05	0.000256	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—EP300—uterine cancer	5.06e-05	0.000256	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—CYP19A1—uterine cancer	5.05e-05	0.000255	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—STK11—uterine cancer	5.05e-05	0.000255	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	4.92e-05	0.000249	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—PIK3CA—uterine cancer	4.92e-05	0.000249	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—PIK3CA—uterine cancer	4.92e-05	0.000249	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	4.91e-05	0.000248	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—VEGFA—uterine cancer	4.79e-05	0.000242	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	4.74e-05	0.00024	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—NRAS—uterine cancer	4.73e-05	0.000239	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	4.65e-05	0.000235	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	4.64e-05	0.000235	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—AKR1B1—uterine cancer	4.58e-05	0.000232	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—STAR—uterine cancer	4.58e-05	0.000232	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	4.53e-05	0.000229	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.52e-05	0.000228	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—ESR1—uterine cancer	4.33e-05	0.000219	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	4.32e-05	0.000219	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	4.09e-05	0.000207	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—KRAS—uterine cancer	4.07e-05	0.000206	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—AKT1—uterine cancer	4.02e-05	0.000203	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—AKT1—uterine cancer	4.02e-05	0.000203	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—MTHFR—uterine cancer	3.79e-05	0.000192	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—STAR—uterine cancer	3.66e-05	0.000185	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—AKR1B1—uterine cancer	3.66e-05	0.000185	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	3.61e-05	0.000183	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—POLD1—uterine cancer	3.59e-05	0.000182	CbGpPWpGaD
Alitretinoin—RARG—Gene Expression—AKT1—uterine cancer	3.49e-05	0.000176	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	3.48e-05	0.000176	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—HRAS—uterine cancer	3.46e-05	0.000175	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—AKR1C1—uterine cancer	3.36e-05	0.00017	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.34e-05	0.000169	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	3.2e-05	0.000162	CbGpPWpGaD
Alitretinoin—RXRG—Gene Expression—AKT1—uterine cancer	3.19e-05	0.000161	CbGpPWpGaD
Alitretinoin—RARB—Gene Expression—AKT1—uterine cancer	3.13e-05	0.000158	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	3.09e-05	0.000156	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—AKT1—uterine cancer	3.06e-05	0.000155	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—AKT1—uterine cancer	3e-05	0.000152	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—AKT1—uterine cancer	3e-05	0.000152	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—RRM2—uterine cancer	3e-05	0.000152	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—DCN—uterine cancer	2.91e-05	0.000147	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—POLD1—uterine cancer	2.87e-05	0.000145	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—CYP11A1—uterine cancer	2.74e-05	0.000139	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—AKR1C1—uterine cancer	2.68e-05	0.000136	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	2.61e-05	0.000132	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—AKR1C3—uterine cancer	2.59e-05	0.000131	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—RRM2—uterine cancer	2.39e-05	0.000121	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—DCN—uterine cancer	2.32e-05	0.000117	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—CYP11A1—uterine cancer	2.19e-05	0.000111	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—PTEN—uterine cancer	2.11e-05	0.000107	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—AKR1C3—uterine cancer	2.07e-05	0.000105	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—STK11—uterine cancer	2.02e-05	0.000102	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—CYP19A1—uterine cancer	2.02e-05	0.000102	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—EP300—uterine cancer	2.01e-05	0.000102	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—STK11—uterine cancer	1.61e-05	8.14e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—CYP19A1—uterine cancer	1.61e-05	8.14e-05	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—AKT1—uterine cancer	1.56e-05	7.91e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—MTHFR—uterine cancer	1.52e-05	7.66e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.51e-05	7.64e-05	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—PIK3CA—uterine cancer	1.49e-05	7.53e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.44e-05	7.29e-05	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—AKT1—uterine cancer	1.22e-05	6.15e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—MTHFR—uterine cancer	1.21e-05	6.12e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.07e-05	5.39e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—PTEN—uterine cancer	8.43e-06	4.26e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—EP300—uterine cancer	8.04e-06	4.07e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—PTEN—uterine cancer	6.73e-06	3.4e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—EP300—uterine cancer	6.42e-06	3.25e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—PIK3CA—uterine cancer	5.95e-06	3.01e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—AKT1—uterine cancer	4.86e-06	2.46e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—PIK3CA—uterine cancer	4.75e-06	2.4e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—AKT1—uterine cancer	3.88e-06	1.96e-05	CbGpPWpGaD
